Business & Market Trends Novo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketing
Key Takeaways Novo Nordisk has sued rival Eli Lilly, alleging the company used deceptive advertising to promote its GLP-1 medications by comparing higher doses of Lilly’s products with lower doses



